Sernova NewsHere is a recap of the latest info on Sernova's outlook & developments taken from their website.
Maybe this will help answer some questions many people keep asking. GL
“During the first half of 2017, we have achieved significant progress in advancing our diabetes and hemophilia programs and have continued to build our intellectual property portfolio reaching new milestones in the development of our global patent portfolio, including coverage of leading indications in major markets,” stated President and CEO, Dr. Philip Toleikis. “We look forward to advancing our ongoing collaboration with a leading, global pharmaceutical company and are confident in our ability to execute on multiple fronts including our upcoming U.S. clinical study earmarked for the second half of 2017, and additional notable collaborations to bring the most innovative and effective regenerative medicine combination products to the forefront,” he added.
Our product development program plans for 2017 includes the following:
Commence a Phase I/II clinical study of our Cell Pouch(TM) in the United States to support our positive results in diabetic patients with hypoglycemia unawareness using human donor islets to further develop the safety and efficacy of our regenerative medicine combination product;
As a member of the HemAcure Consortium who will continue development of IND-enabling cell production and preclinical studies for personalized medicine treatment of hemophilia A consisting of factor VIII releasing therapeutic cells transplanted within Sernova’s implanted prevascularized Cell Pouch. (The HemAcure Consortium is the name of the consortium developing a product for hemophilia A);
Conduct IND-enabling preclinical studies for treatment of hypo-thyroid disease consisting of thyroid hormone releasing tissue transplanted within Sernova’s Cell Pouch;
Production of human stem cell derived cells for diabetes and proof of principle assessment of these differentiated human stem cells for their safety and efficacy within Sernova’s Cell Pouch for the treatment of insulin-dependent diabetes;
Development of novel local immune protection technologies within the Cell Pouch, to further develop and advance Sernova’s therapeutic vision for diabetes of a product consisting of locally immune protected therapeutic cells within the Cell Pouch.
Continue to collaborate with pharmaceutical companies to assess safety and efficacy of our combined technologies in preclinical studies for potential negotiation of a licensing arrangement and commercial development partnership for our diabetes and hemophilia programs.
As of January 31, 2017, Sernova had $5.5 million in cash, cash equivalents, and bank deposits. The company’s net cash used for operating activities was $0.6 million for this quarter. Notably, Management recently purchased a total of 2,044,000 shares as reflected on www.sedar.ca